Core Viewpoint - Huahao Zhongtian Pharmaceutical-B (02563) resumed trading on July 2 after a three-month suspension, with its stock price experiencing a significant drop of 89.16% over four months prior to the suspension [1][4]. Company Performance - The stock price hit a low of 4.28 HKD before the suspension and saw a recovery with over 10% gains on July 2 and 3, culminating in a maximum increase of 44.63% over two days [1][3]. - Trading volume reached approximately 4 million shares per day during the first two trading days post-resumption, marking a new high since the company's listing [3]. Reasons for Suspension - The suspension was primarily due to the company's failure to timely disclose its 2024 annual report, alongside changes in auditors and issues related to the use of IPO proceeds [1][4]. - The company faced delays in compiling necessary information for the annual report, particularly concerning a 91.5 million RMB investment [4][7]. Financial Summary - For the fiscal year ending December 31, 2024, the company reported total revenue of 71.87 million RMB, a year-on-year increase of 7.9%, and a gross profit of 61.09 million RMB, up 30.5% [16]. - The pre-tax loss was recorded at 144 million RMB, a reduction of 24.2% compared to the previous year, with cash and cash equivalents totaling 466.64 million RMB, an increase of 37.1% [15][16]. R&D Developments - The company presented promising clinical trial results for its oral microtubule inhibitor, UTD2, at the ASCO annual meeting, demonstrating significant anti-tumor activity and safety in advanced solid tumor patients [12][18]. - UTD2's combination therapy with PD-1 inhibitors and chemotherapy showed a 100% clinical benefit rate in treating advanced gastric cancer and esophageal squamous cell carcinoma [18]. Market Context - The Hong Kong innovative drug sector is showing signs of recovery, supported by recent policy measures aimed at enhancing the development of innovative drugs [12][14]. - The new policies focus on various aspects of drug development and reimbursement, which could benefit Huahao Zhongtian as its products are already commercialized and included in insurance systems [14].
因500万美元停牌3个月，复牌即涨逾40%的华昊中天医药-B(02563)能否爬出谷底？